A5023632189- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies
- Genital Health and Disease
- Immunotherapy and Immune Responses
- Reproductive tract infections research
- Animal Virus Infections Studies
- Vaccine Coverage and Hesitancy
- Head and Neck Cancer Studies
- Endometrial and Cervical Cancer Treatments
- Research in Social Sciences
- Hepatitis Viruses Studies and Epidemiology
- Preterm Birth and Chorioamnionitis
- Microbial infections and disease research
- T-cell and Retrovirus Studies
- COVID-19 Impact on Reproduction
- Smoking Behavior and Cessation
- Interprofessional Education and Collaboration
- Urinary and Genital Oncology Studies
- Family Support in Illness
- Women's cancer prevention and management
- Colorectal and Anal Carcinomas
- Child and Adolescent Psychosocial and Emotional Development
- HIV/AIDS Research and Interventions
- Viral-associated cancers and disorders
- Viral gastroenteritis research and epidemiology
Tampere University
2015-2024
Tampere University Hospital
2020-2024
Pirkanmaa Hospital District
2021
Karolinska Institutet
2020
The aim of the study was to examine construct validity Three-Factor Eating Questionnaire -R18 (TFEQ-R18), a measure eating behaviour, and evaluate cognitive restraint, uncontrolled emotional in sample adolescent young adult females different weights. Subjects were 2 997 females, aged 17 20 years, who participated phase III human papillomavirus vaccination trial Finland 2004 – 2009. Self-administered questionnaires weight height measurements used. factor structure TFEQ-R18 verified by...
Objective Due to long lag time between infection/cancer diagnoses human papillomavirus (HPV) vaccination programs will deliver vaccine efficacy (VE) estimates against cancer end-points late. Cancer registry follow-up of population-based, randomised trial cohorts vaccinated and unvaccinated women was undertaken for the estimation VE cervical intraepithelial neoplasia grade three invasive (CIN3+). Methods We report interim results with 98 561 person years Finnish Registry -based individually...
Human papillomavirus (HPV) vaccine is efficacious but the real-life effectiveness of gender-neutral and girls-only vaccination strategies unknown. We report a community-randomized trial on protective [(PE) = efficacy (VE) + herd effect (HE)] two among females in virtually HPV naïve population. randomized 33 Finnish communities into Arm A) with AS04-adjuvanted HPV16/18 (11 communities), B) girls hepatitis B-virus (HBV) boys communities) or C) HBV communities). All resident 39,420 40,852 males...
With optimal strategy, human papillomavirus (HPV) vaccines have the potential to control HPV. We assessed vaccine efficacy (VE), herd effect (HE) of HPV vaccination and overall protective effectiveness (PE) against high‐risk infections by type strategy in a community‐randomized trial using bivalent HPV16/18 vaccine. randomized 33 communities gender‐neutral (Arm A), girls hepatitis B‐virus (HBV) boys B) HBV C). Entire 1992–1995 male (40,852) female (39,420) birth cohorts were invited, 11,662...
Human papillomavirus (HPV) vaccination of girls with very high (>90%) coverage has the potential to eradicate oncogenic HPVs, but such is hard achieve. However, herd effect (HE) depends both on HPV type and strategy.
Abstract We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation three-dose, six-month vaccination schedules with the bivalent quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish Indian females, respectively. used a semi-automated Pseudovirion-Based Neutralization Assay observed significantly higher HPV16/18 peak ab-levels as compared to vaccine recipients. Bivalent induced HPV31/33/45/52/58...
The long-term effect of population-level human papillomavirus (HPV) vaccination on the viral ecology untargeted HPVs is poorly understood. We performed an 8-year follow-up 33 communities randomized to gender-neutral HPV16/18 vaccination, girls-only and control without HPV vaccination. 1992/93 1994 birth cohorts were invited in school years 2007/8 2008/9. Follow-up cervico-vaginal sampling at 18 22 age, 4 8 post-vaccination, respectively, attended by 11,396 5,602 participants. types...
Cervical cancer screening programs, including triage tests, need redesigning as human papillomavirus (HPV)-vaccinated women are entering the programs. Methylation markers offer a potential solution to reduce false-positive rates by identifying clinically relevant cervical lesions with progressive potential. In nested case-control study, 9242 who received three-dose HPV16/18-vaccine at ages 12-15 or 18 in community-randomized trial were included. Subsequently, they re-randomized for either...
High-risk human papillomaviruses (hrHPV) cause anogenital and oropharyngeal cancers. HPV-16/18 virus-like particle vaccine formulated with an AS04 adjuvant is very efficacious against hrHPV associated precancers but the herd effects of different vaccination scenarios are not known. Our cluster randomized trial (NCT00534638) assesses overall vaccinating girls vs. boys. In two school-years (2007-2008 2008-2009) we invited 80,272 1992-1995 born early adolescents to a CRT in 33 communities...
Most cervical cancers are caused by vaccine-preventable infections with human papillomaviruses (HPV). The HPV prophylactic vaccines Gardasil and Cervarix have been widely used for >10 years reported to induce high antibody levels. A head-to-head comparison of the responses induced 2 has performed only up 5 years.Among 3300 Finnish females aged 16-17 who got 1 in phase 3 licensure trials, virtually all consented registry-based long-term follow-up. Linkage Maternity Cohort found that they...
Background Human papillomavirus (HPV) vaccination protects against HPV, a necessary risk factor for cervical cancer. We now report results from population-based follow-up of randomised cohorts that provides HPV-type-specific protection invasive Methods Individually and/or cluster HPV-vaccinated and non-vaccinated women were enrolled in 2002–2005. HPV vaccine comprised originally 16–17 year-old 16/18-vaccinated PATRICIA ( NCT00122681 ) 012 trial NCT00169494 participants (2465)...
Phase III clinical trials of human papilloma virus (HPV) vaccination have shown ≥95% efficacy against HPV16/18 associated cervical intraepithelial neoplasia (CIN) Grade 2/3. Long-term surveillance is, however, needed to determine the overall vaccine (VE) CIN3 and invasive carcinoma (ICC). During population-based recruitment between September 2002 March 2003, 1,749 16- 17-year old Finns participated in a multi-national randomized HPV6/11/16/18 (FUTURE II) trial for determination VE positive...
Efficacy of human papillomavirus (HPV) vaccines promises to control HPV infections. However, vaccination programs may lay bare an ecological niche for non-vaccine types. We evaluated type-replacement by type and strategy in a community-randomized trial executed naïve population. Thirty-three communities were randomized gender-neutral with AS04-adjuvanted HPV16/18 vaccine (Arm A), girls hepatitis B-virus (HBV) boys B) HBV C). Resident 1992-95 born (40,852) (39,420) invited. 11,662 20,513...
Control of human papillomavirus (HPV)-related cancers by inclusion HPV vaccination into national programmes is likely. One open question replacement the vaccine types with other high-risk (hr) in era. We studied occurrence adolescent females participating a population-based trial. A total 4,808 16- to 17-year-old from Finland were enrolled 1:1 randomized phase III (PATRICIA) trial efficacy AS04-adjuvanted HPV-16/18 virus-like particle as compared hepatitis virus (HAV) vaccine. infection was...
This community-randomized controlled trial was initiated to assess the overall and herd effects of 2 different human papillomavirus (HPV) immunization strategies in over 80,000 girls boys aged 12–15 y 33 communities Finland (ClinicalTrials.gov NCT00534638). Overall, 14,838 adolescents received HPV-16/18 vaccine (2,440 12,398 girls) 17,338 hepatitis-B virus (HBV) (9,221 8,117 girls). In an interim analysis, safety assessed by active monitoring surveillance via health registry linkage. Active...
We aimed to develop and evaluate the effectiveness of an individualized, long-term support lifestyle counseling approach in promoting healthy physical activity, improving dietary sleeping behaviors, preventing weight gain young females. The approach’s intensity was designed be low enough implementable primary health care. Young women (n = 3,059, age at baseline 17–21 years) attending a population-based human papilloma virus vaccination trial (clinicaltrials.gov identifier: NCT00122681) 15...
Oncogenic non-vaccine human papillomavirus (HPV) types may conceivably fill the vacated ecological niche of vaccine types. The likelihood this differ by risk acquiring HPV infections. We examined occurrence among vaccinated and unvaccinated subgroups 1992-1994 birth cohorts with differing acquisition risks up to 9 years post-implementation vaccination in 33 Finnish communities randomized to: Arm A (gender-neutral HPV16/18 vaccination), B (girls-only hepatitis B-virus (HBV) boys), C HBV...
We studied effectiveness of the AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) vaccine against human papillomavirus (HPV) oropharyngeal infections associated with increase head/neck cancers in western countries. All 38,631 resident adolescents from 1994 to 1995 birth cohorts 33 Finnish communities were invited this community-randomized trial (NCT00534638). During 2008-2009, 11,275 girls and 6,129 boys enrolled three arms 11 each. In Arm A, 90% vaccinated girls/boys, B, received AS04-HPV-16/18...
Abstract Background Human papillomaviruses (HPV) cause several human cancers. Bivalent (Cervarix) and quadrivalent (qGardasil) HPV vaccines both contain virus-like particles of the major oncogenic types 16 18, but also cross-protect against some nonvaccine types. However, data on long-term sustainability cross-reactive antibody responses to are scarce. Methods Serum samples donated 7–12 years after immunization at age 16–17 with bivalent (n = 730) or 337) vaccine were retrieved from...
Human papillomavirus-vaccinated cohorts, irrespective of age, will likely reduce their subsequent screening requirements, thus opening opportunities for global cost reduction and program sustainability. The determinants uptake completion a 3-dose human papillomavirus vaccination by adult women in European context were estimated.
Cervical cancer elimination through human papillomavirus (HPV) vaccination programs requires the attainment of herd effect. Due to its uniquely high basic reproduction number, coverage required achieve effect against HPV type 16 exceeds what is attainable in most populations. We have compared how gender-neutral and girls-only strategies create HPV16 under moderate achieved a population-based, community-randomized trial.
Background. We assessed if risk of developing cervical intraepithelial neoplasia grade 2/3 (CIN2/3) or adenocarcinoma in situ (AIS) is associated with a short interval between menarche and first sexual intercourse (FSI). Methods. A total 1009 Colombian 1012 Finnish females, aged 16–23, who were enrolled the phase 3 trials quadrivalent human papillomavirus (HPV) 6/11/16/18 vaccine had nonmissing data for age FSI. The impact on odds CIN2-3/AIS was evaluated placebo recipients DNA negative to...
Objectives Human papillomavirus (HPV) vaccines protect against infections/conditions which potentially adversely affect quality of life (QoL). We investigated the impact HPV infection on QoL five years post vaccination in 22–23 year-old women and a group controls.Methods Participants were who had either previously been enrolled FUTURE II trial quadrivalent vaccine Finland at age 16–17 (n = 1749), or unvaccinated females birth cohort above those eligible for participation 6534). sent...